Treatment-specific interrupted time series analyses of judicial deference to health technology assessment in Brazil
Open Access
- 12 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Abstract
Background: The use of health rights litigation as a parallel decision-making venue to bypass health technology assessments (HTA) has resulted in unintended inequitable impacts on Latin American health systems since the 1990s. Brazil created a new HTA body in 2011 to promote a transparent and evidence-informed process in the Ministry of Health´s decisions about treatment coverage, but its impact on the judicial system’s provision of specific treatments to patient litigants has not yet been quantitatively evaluated. Methods: We leverage a unique dataset of 3,774 judicial claims for ten of Brazil’s most frequently litigated treatments to conduct the first quasi-experimental evaluation of treatment-specific changes in judicial decisions providing treatments through the national health system. Interrupted time series analyses using ordinary least-squares and logistic fractional response regressions were used to determine if an HTA recommendation was significantly associated with a change in court decisions in favour of litigants following a positive or negative recommendation for national coverage for the ten most litigated treatments in the country. Results: We find no evidence of a statistically significant change in court decisions using ordinary least-squares regression and decreases of smaller than 2.1% in positive court decisions using logistic fractional regression, regardless of whether HTA recommended for or against coverage. Among treatments recommended for coverage, three treatments experienced decreases in positive court decisions ranging from 3.1 to 26.8%. Among treatments recommended against coverage, two treatments experienced decreases in positive decisions ranging from 5.2 to 14.2%, and one treatment experienced a 9.6% increase in positive decisions. Conclusions: Our results demonstrate that nearly all court claims filed for the ten most litigated treatments in Brazil were granted, and HTA recommendations had almost no impact on judicial decisions to grant patient petitions for coverage. Policymakers should be aware that the creation of an HTA does not guarantee that its recommendations will produce a change in court decision making on patient petitions for treatment coverage. To realize the promise of basing difficult decisions on the provision and allocation of health technologies on principles of clinical utility, cost-effectiveness, and equity, the failure to meaningfully incorporate HTA in judicial processes must be addressed.Keywords
Funding Information
- Wellcome Trust (200120/Z/15/Z)
- Research Council of Norway’s GLOBVAC Project (234608)
- Canadian Institutes of Health Research (172982)
- Ontario Ministry of Research, Innovation and Science (ER16-12-197)
This publication has 25 references indexed in Scilit:
- Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 CountriesPharmacoEconomics - Open, 2021
- Chile’s New Constitution: What Right to Health?Hague Journal on the Rule of Law, 2021
- Addressing Challenges in Health Technology Assessment Institutionalization for Furtherance of Universal Health Coverage Through South-South Knowledge Exchange: Lessons From Bhutan, Kenya, Thailand, and ZambiaValue in Health Regional Issues, 2021
- The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?Health Policy, 2021
- Health technology assessment and judicial deference to priority-setting decisions in healthcare: Quasi-experimental analysis of right-to-health litigation in BrazilSocial Science & Medicine, 2020
- Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 DiabetesJAMA, 2018
- MAPPING OF HEALTH TECHNOLOGY ASSESSMENT IN SELECTED COUNTRIESInternational Journal of Technology Assessment in Health Care, 2013
- Simulation-based power calculation for designing interrupted time series analyses of health policy interventionsJournal of Clinical Epidemiology, 2011
- The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countriesHealth Policy, 2010
- Econometric methods for fractional response variables with an application to 401(k) plan participation ratesJournal of Applied Econometrics, 1996